Ritodrine
| Clinical data | |
|---|---|
| Pronunciation | /ˈraɪtoʊdriːn/ RY-toh-dreen |
| Trade names | Pre-Par, Utopar, Yutopar |
| Other names | DU-21220; 4-Hydroxy-β-hydroxy-N-(4-hydroxyphenylethyl)amphetamine; N-(4-Hydroxyphenylethyl)-4-hydroxynorephedrine |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | By mouth, parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | ~56% |
| Metabolism | Hepatic, metabolites are inactive |
| Elimination half-life | 1.7–2.6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.043.512 |
| Chemical and physical data | |
| Formula | C17H21NO3 |
| Molar mass | 287.359 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ritodrine, formerly sold under the brand name Yutopar among others, is a tocolytic drug used to stop premature labor. It was withdrawn from the US market, according to the FDA Orange Book. It was available in oral tablets or as an injection and was typically used as the hydrochloride salt.
The drug acts as a selective β2-adrenergic receptor agonist.
It was first approved for medical use in the United States in 1984.